Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PRPH

PRPH - ProPhase Labs Inc Stock Price, Fair Value and News

$0.16-0.06 (-27.27%)
Market Closed

77/100

PRPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

77/100

PRPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.24

Target 3M

$0.2

Target 6M

$0.22

PRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRPH Price Action

Last 7 days

14.3%

Last 30 days

-64.4%

Last 90 days

-95.7%

Trailing 12 Months

-96.5%

PRPH RSI Chart

PRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRPH Valuation

Market Cap

738.9K

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.15

EV/EBITDA

-0.01

Price/Free Cashflow

-0.07

PRPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.24

Target 3M

$0.2

Target 6M

$0.22

PRPH Fundamentals

PRPH Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

-37.64%

Rev. Growth (Qtr)

-29.19%

PRPH Earnings

Earnings (TTM)

-41.7M

Earnings Growth (Yr)

-3.83%

Earnings Growth (Qtr)

-52.93%

PRPH Profitability

EBT Margin

-680.20%

Return on Equity

-607.84%

Return on Assets

-63.47%

Free Cashflow Yield

-1.4K%

PRPH Investor Care

Shares Dilution (1Y)

93.43%

Diluted EPS (TTM)

-17.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20255.8M5.6M5.1M0
202427.9M20.9M13.8M6.8M
202394.4M78.5M62.7M35.0M
2022111.3M131.3M146.0M122.6M
202127.9M33.4M39.0M79.0M
20209.4M11.4M12.5M14.5M
201912.0M10.5M10.8M9.9M
201812.5M13.8M13.2M13.1M
20174.0M4.8M6.5M9.9M
201615.8M14.6M11.6M4.2M
201521.8M22.2M21.4M20.6M
201423.7M23.5M22.7M22.1M
201323.9M24.0M24.5M25.0M
201220.3M20.5M20.8M22.4M
201115.7M16.3M16.2M17.5M
201000014.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About ProPhase Labs Inc

PRPH
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
 CEO
 WEBSITEprophaselabs.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES129

ProPhase Labs Inc Frequently Asked Questions

PRPH is the stock ticker symbol of ProPhase Labs Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ProPhase Labs Inc is 738.86 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PRPH's fair value in chart for subscribers.

The fair value guage provides a quick view whether PRPH is over valued or under valued. Whether ProPhase Labs Inc is cheap or expensive depends on the assumptions which impact ProPhase Labs Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRPH.

As of Wed Jan 28 2026, PRPH's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRPH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ProPhase Labs Inc has provided -0.352 (multiply by 100 for percentage) rate of return.